Mallinckrodt PLC presented the first results from its two-part pilot study’s 44-week open label extension period, on the efficacy of H.P. Acthar Gel, a repository corticotropin injection, in persistent systemic lupus erythematosus (SLE). Acthar is approved by the U.S. Food and Drug Administration for flares, or for maintenance therapy, in…
Genes regulating the growth factor VEGF signaling pathway are linked to the presence of mouth ulcers in people with systemic lupus erythematosus (SLE), according to a study presented at the European League Against Rheumatism Annual Congress (EULAR 2016) in London on June 10. The finding gives scientists a clue…
An associated risk between lupus and cervical cancer has recently been confirmed in a study titled “Cervical dysplasia and cervical cancer in women with rheumatoid arthritis,” presented at the EULAR Congress 2016 June 8-11 in London. Known as systemic lupus erythematosus or SLE, lupus is a condition characterized by chronic autoimmune…
ImmuPharma, a specialized drug discovery and development pharmaceutical company, announced its Phase 3 clinical trial of Lupuzor (rigerimod), the company’s lead potential breakthrough lupus treatment candidate, has made progress and has begun dosing its first European patients. In its update, ImmunoPharma said the Lupuzor Phase 3 study will enroll…
Researchers at Sun Yat-sen University in China have found that a group of anti-nuclear antibodies that target double stranded DNA, anti-dsDNA, may cause inflammation in systemic lupus erythomatosus (SLE) patients, through the activation of a particular molecular inflammasome. The findings were revealed in the study “Anti-dsDNA antibodies bind to TLR4…
Four key Lupus advocacy groups will host a Lupus Patient-Focused Drug Development Meeting next spring called “Lupus: Patient Voices,” according to a news release. The groups, the Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI), the Lupus and Allied Diseases Association (LADA), and the Lupus Foundation of America (LFA), will lead the…
A patient-centered lupus drug development meeting, “Lupus: Patient Voices”, will be held in spring 2017. The Alliance for Lupus Research (ALR), the Lupus and Allied Diseases Association (LADA), Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI) will organize the event that will focus on patient viewpoints, daily impacts…
Interferon gamma could be a key trigger for lupus, a finding that may provide information leading to new treatments for the autoimmune disease, according to researchers at Penn State College of Medicine. The study, “IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal…
Resolve Therapeutics, a biopharma developing innovative therapies for Systemic Lupus Erythematosus (SLE) and Sjogrens syndrome, will present new data from two clinical studies at the EULAR Annual European Congress of Rheumatology, June 8-11, in London. The company’s scientific founder Dr. Keith Elkon will deliver the oral presentation “Immune Complex Bound…
Sanford Burnham Prebys Medical Discovery Research Institute researchers have uncovered a new protein called P-selectin glycoprotein ligand-1 (PSGL-1) that is involved in the regulation of T-cell immune responses, with implications in autoimmune diseases. The findings have recently been published in Immunity in a study titled “…